UNSPSC 51291503: Befloxatone

This classification denotes a monoamine oxidase inhibitor with the molecular formula C15H18F3NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4H75PAD8M3, chemically known as 2-oxazolidinone, 5-(methoxymethyl)-3-(4-(4,4,4-trifluoro-3-hydroxybutoxy)phenyl)-, (r,(r*,r*))- but generally known as befloxatone, which bears US NIH Compound Identifier 60824. European Medicines Agency schedules Befloxatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05681MIG.

UNSPSC 51291503 Befloxatone is a Commodity code that represents pharmaceutical products and related health supplies procured by state and local health agencies, though recent state and local activity under this code does not demonstrate focused procurement of befloxatone specifically. Instead, the opportunities tagged to this code reflect broader pharmaceutical procurement patterns: naloxone and drug deactivation systems for community health initiatives, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals through cooperative purchasing arrangements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work involves supply of finished pharmaceutical products with manufacturer compliance requirements, wholesaler distribution coordination, pricing negotiation, regulatory certifications (cGMP, DSCSA, FDA), and quarterly or ongoing delivery schedules to designated government health facilities.

Recent activity concentrates in Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor information on direct-to-manufacturer prescription programs and pharmacy benefit capabilities. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026; awarded vendors must maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with contracts effective July 1, 2026. The three opportunities reflect diverse procurement approaches—spot purchases for specific health interventions, exploratory market research for direct contracting models, and large-scale cooperative purchasing frameworks—but none explicitly targets befloxatone as a named commodity.